IP Library Granted Patent US 12,091,601
Granted Patent B2
US 12,091,601 · App. 17/987,004 · Granted Sep 17, 2024

Process to manufacture novel inhibited hydrofluoric acid composition

Inventors: Clay Purdy (Medicine Hat, CA); Markus Weissenberger (Calgary, CA); Karl W. Dawson (Calgary, CA); Kyle G. Wynnyk (Calgary, CA)
Assignee: Dorf Ketal Chemicals FZE
C09K13/08C09K13/06H01L21/30604
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,091,601
App. No.
17/987,004
Granted
Sep 17, 2024
Kind
B2
Abstract

A process for controlling the heat generated during the manufacture an inhibited hydrofluoric acid aqueous composition comprising: hydrofluoric acid in solution; a weak base; and an alkanolamine; said process comprising the steps of: providing a pre-determined amount of weak base; adding a pre-determined amount of said hydrofluoric acid to said weak base and obtaining a solution; adding said alkanolamine to the resulting solution of hydrofluoric acid and weak base; mixing until all components are dissolved; wherein said alkanolamine and hydrofluoric acid are present in a molar ratio of at least 1:1.

Claims (48)

1. An inhibited hydrofluoric acid aqueous composition comprising:

hydrofluoric acid in solution;

a weak base; and

an alkanolamine;

wherein the molar ratio of weak base and alkanolamine to hydrofluoric acid in the composition is at least 1:1, and

wherein the composition is produced by a process comprising:

combining a pre-determined amount of hydrofluoric acid with a predetermined amount of the weak base to obtain a first solution;

adding a predetermined amount of the alkanolamine to the first solution to obtain a second solution; and

mixing the second solution to form the inhibited hydrofluoric acid aqueous composition;

wherein the process is performed such that the inhibited hydrofluoric acid aqueous composition has an HF:alkanolamine:weak base ratio ranging from 1:1:0.02 to 1:1:0.5.

2. The inhibited hydrofluoric acid aqueous composition of claim 1 , wherein the molar ratio of weak base and alkanolamine to hydrofluoric acid in the composition is at least 1.05:1.

3. The inhibited hydrofluoric acid aqueous composition of claim 1 , wherein the molar ratio of weak base and alkanolamine to hydrofluoric acid in the composition is at least 1.1:1.

4. The inhibited hydrofluoric acid aqueous composition of claim 1 , wherein the alkanolamine is selected from the group consisting of monoethanolamine, diethanolamine, triethanolamine, and any combination thereof.

5. The inhibited hydrofluoric acid aqueous composition of claim 1 , wherein the alkanolamine is monoethanolamine.

6. The inhibited hydrofluoric acid aqueous composition of claim 1 , wherein the alkanolamine is diethanolamine.

7. The inhibited hydrofluoric acid aqueous composition of claim 1 , wherein the alkanolamine is triethanolamine.

8. The inhibited hydrofluoric acid aqueous composition of claim 1 , wherein the weak base is selected from the group consisting of lysine, triazole, imidazole, hydantoin, and n-methylimidazole.

9. The inhibited hydrofluoric acid aqueous composition of claim 1 , wherein the weak base is imidazole.

10. The inhibited hydrofluoric acid aqueous composition of claim 1 , wherein the weak base is present in an amount ranging from 0.05 to 0.2 moles for each mole of HF present.

11. The inhibited hydrofluoric acid aqueous composition of claim 1 , wherein the process is performed such that the inhibited hydrofluoric acid aqueous composition has an HF:alkanolamine:weak base ratio ranging from 1:1:0.05 to 1:1:0.1.

12. A glass etching composition comprising:

an inhibited hydrofluoric acid aqueous composition according to claim 1 ; and

a mineral acid.

13. The glass etching composition of claim 12 , wherein the mineral acid is HCl.

14. The glass etching composition of claim 12 , wherein

the alkanolamine is selected from the group consisting of monoethanolamine, diethanolamine, triethanolamine, and any combination thereof; and

the weak base is selected from the group consisting of lysine, triazole, imidazole, hydantoin, and n-methylimidazole.

15. An inhibited hydrofluoric acid aqueous composition comprising:

hydrofluoric acid in solution;

a weak base; and

an alkanolamine;

wherein the molar ratio of weak base and alkanolamine to hydrofluoric acid in the composition is at least 1:1, and

wherein the composition is produced by a process comprising:

preparing a first solution comprising a weak base;

combining a pre-determined amount of hydrofluoric acid with the first solution to obtain a second solution;

adding a predetermined amount of the alkanolamine to the second solution to obtain a third solution; and

mixing the third solution to form the inhibited hydrofluoric acid aqueous composition,

wherein the process is performed such that the inhibited hydrofluoric acid aqueous composition has an HF:alkanolamine:weak base ratio ranging from 1:1:0.02 to 1:1:0.5.

16. The inhibited hydrofluoric acid aqueous composition of claim 15 , wherein the process is performed such that the inhibited hydrofluoric acid aqueous composition has an HF:alkanolamine:weak base ratio ranging from 1:1:0.05 to 1:1:0.1.

17. the inhibited hydrofluoric acid aqueous composition of claim 15 , wherein the alkanolamine is selected from the group consisting of monoethanolamine, diethanolamine, triethanolamine, and any combination thereof.

18. The inhibited hydrofluoric acid aqueous composition of claim 15 , wherein the weak base is selected form the group consisting of lysine, triazole, imidazole, hydantoin, and n-methylimidazole.

19. A glass etching composition comprising:

an inhibited hydrofluoric acid aqueous composition according to claim 15 , and

a mineral acid.

20. The glass etching composition of claim 19 , wherein

the mineral acid is HCl;

the alkanolamine is selected form the group consisting of monoethanolamine, diethanolamine, triethanolamine, and any combination thereof; and

the weak base is selected from the group consisting of lysine, triazole, imidazole, hydantoin, and n-methylimidazole.

Assignments (4)
SECURITY INTEREST Recorded Dec 12, 2023
From: DORF KETAL CHEMICALS FZE
To: HSBC BANK MIDDLE EAST LIMITED
Reel/Frame 065878/0104 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PRIOR ERRONEOUS RECORDATION OF ASSIGNMENT APPLICATION NUMBERS: 15614284, 17148881 PREVIOUSLY RECORDED ON REEL 063118 FRAME 0689. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 17, 2023
From: FLUID ENERGY GROUP LTD.
To: DORF KETAL CHEMICALS FZE
Reel/Frame 063695/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2023
From: FLUID ENERGY GROUP LTD.
To: DORF KETAL CHEMICALS FZE
Reel/Frame 063118/0689 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2022
From: PURDY, CLAY; WEISSENBERGER, MARKUS; DAWSON, KARL W.; WYNNYK, KYLE G.
To: FLUID ENERGY GROUP LTD.
Reel/Frame 061768/0689 →
Priority Claims (1)
CA CA 3083522 · Jun 12, 2020 · national
Continuity (2)
Division 17338865 · Jun 4, 2021
Related Publication 20230080049A1 · Mar 16, 2023